Shared genetic components between brain regions identify potential therapeutic targets for Alzheimer’s disease by integrative proteomic analysis

Genome‐wide association studies (GWAS) have identified >30 genetic loci associated with Alzheimer’s disease (AD). However, how those variants impact protein expression in different brain regions remain elusive. Large‐scale quantitative proteomic datasets of AD postmortem brain tissues have become available with the breakthrough of high‐throughput mass spectrometry‐based technologies. Thus, we utilized these datasets to understand brain region‐specific molecular pathways underlying AD pathogenesis and their potential drug targets.